A4250

odevixibat · Albireo (an Ipsen company)

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for A4250, covering 2017-02-23 to 2025-07-10. Get the full timeline:

Most recent: Clinical Trial Update: Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC [Phase 3]